Topical Delivery of Apremilast Loaded Nanostructured Lipid Carrier Based Hydrogel for Psoriasis Therapy
S. M. Sindhoor & Marina Koland · Journal of Pharmaceutical Research International · 2021
Background: Apremilast (APR) is an orally administered selective phosphodiesterase 4 inhibitor approved to treat plaque psoriasis and psoriatic arthritis and is available as an oral tablet formulation. However, its systemic side effects limit its application. The low solubility a...
Open access
Research Article
10.9734/jpri/2021/v33i28B31531